Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
MoonLake Immunotherapeutics (MLTX) had Return on Investments of -19.74% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-69.71M |
|
-- |
|
-- |
|
$70.02M |
|
$-70.02M |
|
$0.94M |
|
$-69.08M |
|
$-69.08M |
|
$-69.71M |
|
$-69.71M |
|
$-69.71M |
|
$-69.71M |
|
$-70.02M |
|
$-69.18M |
|
71.27M |
|
71.27M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$396.64M |
|
$0.53M |
|
$3.73M |
|
$400.37M |
|
$46.11M |
|
$99.02M |
|
$100.24M |
|
$146.35M |
|
$254.02M |
|
$254.02M |
|
$254.02M |
|
72.13M |
|
| Cash Flow Statement Financials | |
$-66.29M |
|
$0.10M |
|
$30.64M |
|
$334.52M |
|
$298.49M |
|
$-36.03M |
|
$13.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.60 |
|
-- |
|
-- |
|
0.28 |
|
0.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-66.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-27.44% |
|
-27.44% |
|
-17.41% |
|
|
Return on Investments |
-19.74% |
$3.52 |
|
$-0.93 |
|
$-0.93 |
|